InSea2 Reduces Glycemic ResponseInSea2 Reduces Glycemic Response
December 1, 2009
RIMOUSKI, QuebecinnoVactiv Inc. reported InSea2 produced statistically significant results in a recently completed human clinical trial. In a randomized crossover, double blind, placebo-controlled human clinical trial led by the Institute of Nutraceuticals and Functional Foods of Laval University, 500 mg of InSea2 induced a 44-percent decrease in the normal glycemic response that follows ingestion of a standardized meal (white bread, P=0.046) in 23 healthy volunteers. InSea2 also induced a 22-percent reduction in initial insulin production (P=0.045) and an overall 5.9-percent reduction in the area under the curve of the insulin response (P=0.031). InSea2 improved insulin sensitivity by 6.9 percent (Cederholm index, P=0.047) after a single use of the product. The results of this study will be presented at the Experimental Biology meeting in Anaheim, Calif., April 24 to 28, 2010.
We are very excited by these results, confirming the efficacy of InSea2 in humans, said Jocelyn Bérubé, scientific director, health & nutrition at innoVactiv. The fact that we reached statistically significant results at low dosage levels is encouraging, especially from a pure science perspective.
You May Also Like
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023